A spot­light schiz­o­phre­nia drug in Neu­ro­crine's $2B Take­da deal flunks its first ma­jor test. But it's not giv­ing up yet

When Take­da spun out a pipeline of ex­per­i­men­tal psy­chi­a­try drugs to Neu­ro­crine in a $2 bil­lion deal amid a post-merg­er shake­out, R&D chief Andy Plump de­scribed the ther­a­pies as “very in­ter­est­ing but still dif­fi­cult.”

On Tues­day, we got some idea of how dif­fi­cult.

San Diego-based Neu­ro­crine re­vealed that one of the three spot­light clin­i­cal pro­grams they’d ac­quired failed the pri­ma­ry end­point in a Phase II tri­al for schiz­o­phre­nia, reg­is­ter­ing a neg­a­tive out­come on the change from base­line in the pos­i­tive and neg­a­tive syn­drome scale/neg­a­tive symp­tom fac­tor score (PANSS NS­FS).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.